Radiopharmaceutical company Lantheus Holdings (NASDAQ: LNTH) missed Wall Street’s revenue expectations in Q2 CY2025, with sales falling 4.1% year on year to $378 million. The company’s full-year revenue guidance of $1.49 billion at the midpoint came in 5% below analysts’ estimates. Its non-GAAP profit of $1.57 per share was 6.3% below analysts’ consensus estimates.

Is now the time to buy LNTH? Find out in our full research report (it’s free).

StockStory’s Take

Lantheus’ second quarter results were met with a significant negative market reaction, as both revenue and non-GAAP earnings fell short of Wall Street’s expectations. Management attributed the underperformance primarily to competitive pricing pressures in the PSMA PET imaging market, particularly affecting its flagship product, PYLARIFY. CEO Brian Markison acknowledged the challenging environment, stating, “We made the intentional decision to remain disciplined with our pricing strategy, even at the cost of losing select accounts rather than chase volume and harm the long-term value of our PSMA PET franchise.” The company’s refusal to match aggressive competitor discounts, combined with slower growth in large institutional accounts, drove volume losses and pressured margins.

Looking ahead, Lantheus’ updated guidance reflects ongoing pricing headwinds and slower anticipated growth in its core radiopharmaceutical franchises. Management outlined a cautious outlook for PYLARIFY, expecting continued net price declines and only low-single-digit volume growth relative to more robust market expansion. CFO Robert Marshall emphasized that stabilization of PYLARIFY and successful integration of recent acquisitions are top priorities, while also highlighting the potential for new product launches to diversify revenue. As President Paul Blanchfield noted, “We are preparing to commercialize our new PSMA PET agent…which will ultimately improve both patient and customer access.”

Key Insights from Management’s Remarks

Management highlighted competitive pricing pressure in the PSMA PET segment, intentional pricing discipline, and portfolio diversification efforts as the most impactful themes this quarter.

• PYLARIFY pricing discipline: Lantheus deliberately refused to match steep discounts from an F-18 competitor, leading to renegotiations and the loss of some accounts, but aimed to protect long-term franchise value and clinical differentiation.
• Shift in customer mix: The company’s largest accounts, which remain concentrated in institutional settings, grew at a slower pace than the overall market, while new strategic partnerships with smaller, high-growth accounts outperformed in volume expansion.
• Portfolio diversification via acquisitions: The recent acquisitions of Evergreen and Life Molecular Imaging (LMI) contributed to an expanded pipeline and diversified revenue streams, including the addition of Neuraceq for Alzheimer's diagnostics.
• Regulatory progress and product development: The FDA accepted an NDA for a new PYLARIFY formulation, which is expected to increase batch size, improve production efficiency, and expand geographic reach if approved in 2026.
• Increased focus on clinical education: Management is investing in medical affairs to communicate PYLARIFY’s clinical attributes versus competing agents, especially as anecdotal reports of false positives with rival products emerge.

Drivers of Future Performance

Lantheus anticipates continued pricing headwinds and a slow recovery in its core markets, with new launches and acquisitions expected to gradually support revenue diversification.

• PYLARIFY volume and pricing dynamics: Management expects PYLARIFY volumes to grow at a low-single-digit rate, lagging the broader PSMA PET market, while net price is projected to decline further due to contract renegotiations and government reimbursement resets.
• Product pipeline expansion: The near-term launch of a new PSMA PET agent, expanded Neuraceq indications, and advancing late-stage Alzheimer’s and neuroendocrine tumor diagnostics are expected to offset pressure on existing products and drive long-term growth.
• Integration of recent acquisitions: The successful onboarding and commercialization of LMI and Evergreen are critical for revenue diversification. Management highlighted that Neuraceq is showing double-digit growth and will be central to Lantheus’ expansion in neurology imaging.

Catalysts in Upcoming Quarters

In upcoming quarters, our analysts will be watching (1) the pace of stabilization and potential recovery in PYLARIFY’s volumes and pricing, (2) the commercial execution and integration of the Neuraceq and Evergreen acquisitions, and (3) regulatory progress and preparations for launching the new PSMA PET formulation. The success of Lantheus’ pipeline in Alzheimer’s and neuroendocrine imaging will also serve as important milestones.

Lantheus currently trades at $56, down from $72.64 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.